Table 2 Spleen tyrosine kinase inhibition therapy in lupus animal models
Reference | Drug | Duration | Model | Outcome |
|---|---|---|---|---|
Bahjat et al. [50] | R788 | 24 to 34 weeks, 20 to 40 mg/kg twice daily, orally | Lupus-prone mice (NZB/NZW) | Delayed proteinuria and kidney dysfunction and prolonged survival |
Deng et al. [52] | R788 | 3 to 10 g/kg of diet, up to 16 weeks, orally | Lupus-prone mice (MRL/lpr and BAX/BAK) | Decreased skin and renal disease |